Pharmacology, Pharmacokinetics and Pharmacodynamics of Eculizumab, and Possibilities for an Individualized Approach to Eculizumab.

Kioa Lente WijnsmaRob Ter HeineDirk Jan A R MoesSaskia LangemeijerSaskia E M ScholsElena B VolokhinaLambertus P van den HeuvelJack F M WetzelsNicole C A J van de KarRoger J Brüggemann

Published in: Clinical pharmacokinetics (2020)

Eculizumab is the first drug approved for the treatment of complement-mediated diseases, and current dosage schedules result in large interindividual drug concentrations. This review provides insight into the pharmacokinetic and pharmacodynamic properties of eculizumab, both for reported on-label (paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, generalized myasthenia gravis) and off-label (hematopoietic stem cell transplantation-associated thrombotic microangiopathy) indications. Furthermore, we discuss the potential of therapeutic drug monitoring to individualize treatment and reduce costs.

Keyphrases

atrial fibrillation
emergency department
obstructive sleep apnea
combination therapy
risk assessment
sleep apnea
depressive symptoms
catheter ablation